CellBank Australia

Cell Line Information Sheet for LIM2099

Cell Line Designation	LIM2099
CellBank Catalogue No.	CBA-0164
Lot Number	01640211E
Passage Number	23
Total Cell Number	2.3x 10^6 cells
Expected Cell Viability	94%
Brief Description	Liver metastasis, moderately differentiated sclerosing adenocarcinoma
Organism	Human (*Homo Sapiens*)
Growth Properties	Adherent
Morphology	Epithelial
Image	
Growth Medium	RPMI1640 (with 2mM L-Glutamine + 25mM Hepes) +10%FCS, Insulin 0.6µg/ml, Hydrocortisone 1µg/ml, 1-Thioglycerol 10µM
Subcultivation Ratio	Optimal split ratio 1:4-1:6 using 0.05%Trypsin/EDTA at 37°C for 5-10 minutes. Seeding density 0.8 x 10^4 cells/cm^2
Establishing and Maintaining your Culture	Cells incubated at 37°C with 5% CO_2. Refer to Technical & Customer Service Information pamphlet for more information..
Cryoprotectant Medium	10% DMSO + 90% FCS

CellBank Australia
214 Hawkesbury Road
Westmead, NSW, 2145
Australia

P: +61 (0)2-8865-2850
F: +61 (0)2-9687-2120
www.cellbankaustralia.com
info@cellbankaustralia.com

CellBank Australia

Cell Line Information Sheet for LIM2099

Biosafety Level	Cell line of human origin. CellBank Australia recommends that cell lines be handled at category PC-2* containment level. *AS/NZS 2243.3:2010
Use Restrictions	These cells are distributed for research purposes only - refer to the Material Transfer Agreement (MTA).
Safety Precaution	Where cell lines are shipped as frozen ampoules there is a small risk that the ampoule may be pressurised, due to the expansion of trapped liquid nitrogen and could explode on warming. It is recommended that persons handling ampoules of frozen cells wear appropriate personal protective equipment including laboratory coat, insulated gloves and a full protective face shield.
Handling Procedure for Frozen Cells	Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability. Remove protective cryoflex layer around the ampoule prior to thawing. A precentrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.
Additional Information	Liver metastasis from patient with previous colon carcinoma, male, "consistent with origin of gall bladder", A33 negative, mutated beta-catenin and K-Ras, expresses vimentin, MSS
Depositor	Professor Tony Burgess Ludwig Institute for Cancer Research Ltd, Melbourne - Australia
References	Whitehead, R.H *et al.* Retention of tissue-specific phenotype in a panel of colon carcinoma cell lines: Relationship to clinical correlates. Immunol Cell Biol. 1992; 70: 227-236 Zhang H. *et al.* Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. Int.J.Cancer 2009 July15; 125(2):297-307
CellBank Warranty	While CellBank Australia uses reasonable efforts to include accurate and up-to date information on this product sheet, CellBank Australia makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. CellBank Australia does not warrant that such information has been confirmed to be accurate.
Disclaimers	This product is sent with the condition that you are responsible for its safe storage, handling, and use. CellBank Australia is not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to insure authenticity and reliability of strains on deposit, CellBank Australia is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the MTA for further details regarding the use of this product. The MTA is also available on our Web site at www.cellbankaustralia.com

CellBank Australia
214 Hawkesbury Road
Westmead, NSW, 2145
Australia

P: +61 (0)2-8865-2850
F: +61 (0)2-9687-2120
www.cellbankaustralia.com
info@cellbankaustralia.com